Alexandria Venture Investments, LLC - 21 Oct 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: 10%+ Owner
Signature: By: ALEXANDRIA REAL ESTATE EQUITIES, INC., a Maryland corporation, managing member By: /s/ Dean A. Shigenaga Chief Financial Officer
Issuer symbol: XLO
Transactions as of: 21 Oct 2021
Net transactions value: $0
Form type: 3
Filing time: 21 Oct 2021, 20:59:46 UTC
Previous filing: 01 Jun 2021
Next filing: 26 Oct 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	XLO	Series B convertible preferred stock							21 Oct 2021	Common stock	166,423		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The preferred stock is convertible into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering, for no additional consideration.